FREQUENCY THERAPEUTICS, INC. (FREQ): Price and Financial Metrics
GET POWR RATINGS... FREE!
FREQ POWR Grades
- FREQ scores best on the Value dimension, with a Value rank ahead of 65.56% of US stocks.
- The strongest trend for FREQ is in Momentum, which has been heading down over the past 52 weeks.
- FREQ ranks lowest in Sentiment; there it ranks in the 4th percentile.
FREQ Stock Summary
- FREQ's went public 2.16 years ago, making it older than just 5.08% of listed US stocks we're tracking.
- With a year-over-year growth in debt of 1,952.08%, Frequency Therapeutics Inc's debt growth rate surpasses 99.05% of about US stocks.
- In terms of volatility of its share price, FREQ is more volatile than 99.76% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to Frequency Therapeutics Inc are CCXI, RESN, SWTX, ACRS, and MNOV.
- FREQ's SEC filings can be seen here. And to visit Frequency Therapeutics Inc's official web site, go to www.frequencytx.com.
FREQ Valuation Summary
- FREQ's price/earnings ratio is -5; this is 113.7% lower than that of the median Healthcare stock.
- FREQ's EV/EBIT ratio has moved up 16.9 over the prior 23 months.
- FREQ's price/sales ratio has moved NA NA over the prior 23 months.
Below are key valuation metrics over time for FREQ.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| FREQ | 2021-08-31 | 7.5 | 1.6 | -5.0 | -3.3 |
| FREQ | 2021-08-30 | 7.6 | 1.6 | -5.0 | -3.3 |
| FREQ | 2021-08-27 | 7.7 | 1.6 | -5.1 | -3.4 |
| FREQ | 2021-08-26 | 7.6 | 1.6 | -5.0 | -3.3 |
| FREQ | 2021-08-25 | 7.6 | 1.6 | -5.0 | -3.3 |
| FREQ | 2021-08-24 | 7.5 | 1.6 | -5.0 | -3.3 |
FREQ's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- FREQ has a Quality Grade of D, ranking ahead of 8.89% of graded US stocks.
- FREQ's asset turnover comes in at 0.147 -- ranking 225th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows FREQ's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.147 | 1 | -0.828 |
| 2021-03-31 | 0.145 | 1 | -1.583 |
| 2020-12-31 | 0.161 | 1 | 4.957 |
| 2020-09-30 | 0.145 | 1 | 0.830 |
| 2020-06-30 | 0.220 | 1 | 0.575 |
| 2019-12-31 | 0.216 | 1 | 1.319 |
FREQ Price Target
For more insight on analysts targets of FREQ, see our FREQ price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $13.50 | Average Broker Recommendation | 1.7 (Moderate Buy) |
FREQ Stock Price Chart Interactive Chart >
FREQ Price/Volume Stats
| Current price | $5.18 | 52-week high | $58.37 |
| Prev. close | $5.33 | 52-week low | $5.06 |
| Day low | $5.06 | Volume | 124,933 |
| Day high | $5.42 | Avg. volume | 616,894 |
| 50-day MA | $6.64 | Dividend yield | N/A |
| 200-day MA | $12.53 | Market Cap | 179.24M |
FREQUENCY THERAPEUTICS, INC. (FREQ) Company Bio
Frequency Therapeutics, Inc. is a clinical-stage biotechnology company. It engages in the development of small molecule drugs that activate progenitor cells within the body to restore healthy tissue. T
Latest FREQ News From Around the Web
Below are the latest news stories about Frequency Therapeutics Inc that investors may wish to consider to help them evaluate FREQ as an investment opportunity.
Frequency Therapeutics, Inc. (FREQ) Reports Q3 Loss, Lags Revenue EstimatesFrequency Therapeutics, Inc. (FREQ) delivered earnings and revenue surprises of -32.73% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock? |
Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial ResultsLEXINGTON, Mass., November 15, 2021--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today announced business updates and financial results for the third quarter ended September 30, 2021. |
Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Multiple SclerosisLEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a persons innate regenerative potential to restore function, today will host a virtual R&D event. The webcast can be accessed here. We look forward to highlighting the extensive data supporting our Phase 2b study (FX-322-208) in patients with sensorineural hearing loss (SNHL), where we have seen clear clinical improve |
Analysts Estimate Frequency Therapeutics, Inc. (FREQ) to Report a Decline in Earnings: What to Look Out forFrequency Therapeutics, Inc. (FREQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Frequency Therapeutics, Inc. (NASDAQ:FREQ) Shares Purchased by Deutsche Bank AGDeutsche Bank AG lifted its stake in Frequency Therapeutics, Inc. (NASDAQ:FREQ) by 35.3% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 25,261 shares of the company’s stock after purchasing an additional 6,596 shares during the quarter. Deutsche Bank AG’s holdings in Frequency Therapeutics were worth $252,000 at the end of the most recent quarter. […] |
FREQ Price Returns
| 1-mo | -17.52% |
| 3-mo | -34.51% |
| 6-mo | -42.19% |
| 1-year | -81.95% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -85.31% |
| 2020 | 101.14% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...